Information Provided By:
Fly News Breaks for February 4, 2019
ABMD
Feb 4, 2019 | 18:51 EDT
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $480 price target on Abmiomed, saying there are nuances to the recent issuance of a "Dear Doctor" letter related to the Impella RP. The analyst notes that 16 of the 23 patients enrolled in the PAS "would not have met the enrollment criteria for the premarket study", so the survival in patients on protocal would have been higher than the 17% reported at 43% or 57%. O'Brien expects the impact of the letter to be minimal to RP utilization, stating that the opportunity for the program "remains healthy".
News For ABMD From the Last 2 Days
There are no results for your query ABMD